MX2020002684A - Composiciones topicas. - Google Patents

Composiciones topicas.

Info

Publication number
MX2020002684A
MX2020002684A MX2020002684A MX2020002684A MX2020002684A MX 2020002684 A MX2020002684 A MX 2020002684A MX 2020002684 A MX2020002684 A MX 2020002684A MX 2020002684 A MX2020002684 A MX 2020002684A MX 2020002684 A MX2020002684 A MX 2020002684A
Authority
MX
Mexico
Prior art keywords
composition
hormone
present disclosure
active agent
topical compositions
Prior art date
Application number
MX2020002684A
Other languages
English (en)
Inventor
Steven C Quay
Avadhesh S Kushwaha
Edward T Kisak
John M Newsam
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of MX2020002684A publication Critical patent/MX2020002684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona una composición tópica novedosa que comprende al menos un agente activo y un método para preparar la composición; ciertos compuestos han sido combinados para preparar una composición estable que comprende al menos un agente activo tal como moduladores selectivos del receptor de estrógeno e inhibidoes de aromatasa; la presente descripción también proporciona métodos para el tratamiento de trastornos de mama dependientes de hormonas y del tracto reproductivo dependientes de hormonas.
MX2020002684A 2017-09-11 2018-09-10 Composiciones topicas. MX2020002684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556920P 2017-09-11 2017-09-11
PCT/US2018/050193 WO2019051368A1 (en) 2017-09-11 2018-09-10 TOPICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
MX2020002684A true MX2020002684A (es) 2020-09-25

Family

ID=65634484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002684A MX2020002684A (es) 2017-09-11 2018-09-10 Composiciones topicas.

Country Status (12)

Country Link
US (1) US20200268690A1 (es)
EP (1) EP3681490A4 (es)
JP (1) JP2020533343A (es)
KR (1) KR20200051690A (es)
CN (1) CN111212635A (es)
AU (1) AU2018330314A1 (es)
CA (1) CA3074595A1 (es)
IL (1) IL272944A (es)
MX (1) MX2020002684A (es)
SG (1) SG11202002104XA (es)
TW (1) TW201919608A (es)
WO (1) WO2019051368A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
TW202510843A (zh) * 2023-07-19 2025-03-16 美商阿托薩醫療公司 因多昔芬（ｅｎｄｏｘｉｆｅｎ）組合物及其使用方法及其合成

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
AU2016247674A1 (en) * 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders

Also Published As

Publication number Publication date
SG11202002104XA (en) 2020-04-29
WO2019051368A1 (en) 2019-03-14
EP3681490A4 (en) 2021-11-03
IL272944A (en) 2020-04-30
CA3074595A1 (en) 2019-03-14
JP2020533343A (ja) 2020-11-19
AU2018330314A1 (en) 2020-03-19
KR20200051690A (ko) 2020-05-13
US20200268690A1 (en) 2020-08-27
TW201919608A (zh) 2019-06-01
EP3681490A1 (en) 2020-07-22
CN111212635A (zh) 2020-05-29

Similar Documents

Publication Publication Date Title
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
EA201690006A1 (ru) Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
NZ746954A (en) Thiazolopyridine derivatives as gpr119 agonists
MX2022005780A (es) Moduladores de receptores estrogenicos.
PH12019502646A1 (en) Pyrazole magl inhibitors
MY189941A (en) Pyrazole compounds and method for making and using the compounds
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX370450B (es) Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
NZ743651A (en) Benzothiophene-based selective estrogen receptor downregulators
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
PH12013500970B1 (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
JOP20190262A1 (ar) مثبطات بيرازول magl
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
MX2020002684A (es) Composiciones topicas.
HK1248140A1 (zh) 用於治疗癌症或免疫性疾病的细胞外基质组合物
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
EA201890967A1 (ru) Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство
JOP20210029A1 (ar) تركيبات زيتية موضعية
NZ713614A (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2019054891A3 (en) Trpv2 antagonists
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.